Timothy P. Lynch’s Stonepine Capital Portfolio: Top 5 Healthcare Stocks

2. CTI BioPharma Corp. (NASDAQ:CTIC)

Stonepine Capital’s Stake Value: $23,495,000

Percentage of Stonepine Capital’s 13F Portfolio: 10.69%

Number of Hedge Fund Holders: 11

CTI BioPharma Corp. (NASDAQ:CTIC) is a company investing in cell therapies for blood related cancers. After one of its products failed to deliver desired results for patients hospitalized due to COVID-19, Lake Street analyst Thomas Flaten on October 4 regarded the news as a buying opportunity and kept a Buy rating on the stock with a $15 price target. 

CTI BioPharma Corp. (NASDAQ:CTIC) posted its Q3 results on November 12. EPS in the period came in at -$0.26, missing estimates by -$0.01. Samuel Isaly’s OrbiMed Advisors is one of the leading stakeholders of the company as of September 2021.

Out of the 867 hedge funds monitored by Insider Monkey as of the third quarter, 11 funds were bullish on CTI BioPharma Corp. (NASDAQ:CTIC), with stakes valued at $86.9 million. This is compared to 10 funds holding a position in CTI BioPharma Corp. (NASDAQ:CTIC) in Q2, with a total stake value of $74.3 million.